ASTRAZENECA WKN: 886455 ISIN: GB0009895292 Kürzel: AZN Forum: Aktien Thema: Hauptdiskussion

130,92 USD
-1,30 %-1,73
23. Dec, 23:20:00 Uhr, Nasdaq OTC
Kommentare 2.737
oxanabanana
oxanabanana, 24.09.2021 10:31 Uhr
0
24 September 2021 Positive high-level results from the PROpel Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus standard-of-care abiraterone as a 1st-line treatment for men with metastatic castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair (HRR) gene mutations.
oxanabanana
oxanabanana, 23.09.2021 8:19 Uhr
0
23 September 2021 AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisastion of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.
oxanabanana
oxanabanana, 21.09.2021 8:29 Uhr
0
21 September 2021 AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland to ensure the Company’s global supply network is fit for future growth.
oxanabanana
oxanabanana, 21.09.2021 8:29 Uhr
0
AstraZeneca to invest $360m in advanced manufacturing facility in Ireland
BankerBilo
BankerBilo, 20.09.2021 18:38 Uhr
0
Nicht schlecht...
oxanabanana
oxanabanana, 20.09.2021 14:59 Uhr
0
Zum Mond wird die nicht fliegen, bleibt aber im Vergleich zum schwachen Markt stabil
Aktenhai
Aktenhai, 19.09.2021 20:43 Uhr
0
da wird ja eure Aktie am Montag zum Mond fliegen nach den Mega News
oxanabanana
oxanabanana, 19.09.2021 20:19 Uhr
0
Und was war so lustig um kurz nach halb acht?
Beamta
Beamta, 19.09.2021 7:36 Uhr
0
🤣
dynamic
dynamic, 18.09.2021 22:11 Uhr
0
🤦🏻‍♂️
oxanabanana
oxanabanana, 18.09.2021 19:01 Uhr
0
18 September 2021 Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
dynamic
dynamic, 18.09.2021 15:54 Uhr
1
Hier gibt es fast nur noch posts von Oxana, schon seltsam. Hast nix besseres zu tun ?
oxanabanana
oxanabanana, 18.09.2021 15:31 Uhr
0
18 September 2021 Detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), demonstrated superior progression-free survival (PFS) versus trastuzumab emtansine (T-DM1), a HER2-directed ADC currently approved to treat patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. Results were presented today in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2021.
oxanabanana
oxanabanana, 18.09.2021 15:30 Uhr
0
18 September 2021 Detailed primary results from the positive Phase II DESTINY-Lung01 trial of Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), showed a robust and durable tumour response in previously treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC). Results presented during a late-breaking Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2021 and simultaneously published in The New England Journal of Medicine confirm Enhertu as the first HER2-directed therapy to show a strong tumour response in this patient population.
oxanabanana
oxanabanana, 17.09.2021 21:02 Uhr
0
17 September 2021 Detailed results from the positive Phase II DESTINY-Gastric02 trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), provided a clinically meaningful and durable tumour response in patients with HER2-positive metastatic and/or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with a trastuzumab-containing regimen. Results were presented during a late-breaking mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021.
oxanabanana
oxanabanana, 17.09.2021 14:18 Uhr
0
17 September 2021 Results from the large, randomised COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).
Mehr zu diesem Wert
Thema
1 ASTRAZENECA Hauptdiskussion
2 Short
Meistdiskutiert
Thema
1 BTC/USD Hauptdiskussion -0,41 %
2 MicroStrategy -6,91 %
3 VALNEVA SE Hauptdiskussion -5,53 %
4 NVIDIA Hauptdiskussion +3,36 %
5 ATOS Hauptdiskussion +10,00 %
6 NEL ASA Hauptdiskussion -3,39 %
7 BAYER Hauptdiskussion +0,23 %
8 PILBARA MINERALS Hauptdiskussion +1,92 %
9 Vulcan Energy Resources Hauptdiskussion -5,11 %
10 RHEINMETALL Hauptdiskussion -0,99 %
Alle Diskussionen
Aktien
Thema
1 MicroStrategy -6,91 %
2 VALNEVA SE Hauptdiskussion -5,53 %
3 NVIDIA Hauptdiskussion +3,36 %
4 ATOS Hauptdiskussion +10,00 %
5 NEL ASA Hauptdiskussion -3,39 %
6 BAYER Hauptdiskussion +0,23 %
7 PILBARA MINERALS Hauptdiskussion +1,92 %
8 Vulcan Energy Resources Hauptdiskussion -5,11 %
9 RHEINMETALL Hauptdiskussion -0,99 %
10 Vivoryon Therapeutics +0,05 %
Alle Diskussionen